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ABSTRACT
Introduction: We evaluated the safety and efficacy of protamine 
administration, guided by activated clotting time, for the im-
mediate femoral arterial sheath removal in patients undergoing 
percutaneous coronary intervention with unfractionated heparin 
in order to propose an algorithm for clinical practice. Methods: 
Prospective study with consecutive patients with stable angina 
or low-to-moderate risk acute coronary syndrome. We compared 
patients with an early removal of the arterial sheath to those 
whose sheath removal was based on a standard protocol. 
Results: The early removal group (n = 149) had lower access 
manipulation time than the conventional group (58.3 ± 21.4 
minutes vs. 355.0 ± 62.9 minutes; p  <  0.01), mainly due to 
a reduced time to sheath removal (42.3 ± 21.1 minutes vs. 
338.6 ± 61.5 minutes; p < 0.01), with no impact on the dura-
tion of femoral compression (16.0 ± 3.6 minutes vs. 16.4 ± 
5.1 minutes; p = 0.49). There was no stent thrombosis during 
hospitalization and no significant differences in the incidence 
of major vascular or bleeding events. The incidence of other 
bleeding events leading to a prolonged in-hospital length of 
stay was lower in the early removal group (1.3% vs. 5.1%; 
p = 0.05). Conclusions: The selective use of an approach for 
immediate femoral sheath removal, based on activated clotting 
time guidance and protamine administration, is a safe and 
effective option in patients undergoing percutaneous coronary 
intervention by femoral access. 
 
 
 
 
 
DESCRIPTORS: Protamines. Heparin. Percutaneous coronary 
intervention. Femoral artery. Anticoagulants.
Instituto do Coração, Universidade de São Paulo, São Paulo, SP, Brazil. Correspondence to: Pedro Alves Lemos Neto. Avenida Dr. Enéas 
de Carvalho Aguiar, 44, bloco I, 3º andar – CEP: 05403-000 – São 
Paulo, SP, Brazil
E-mail: pedro.lemos@incor.usp.br
Received: 04/21/2014 • Accepted: 06/30/2014
RESUMO
Remoção Precoce do Introdutor Arterial Após 
Intervenção Coronária Percutânea por Via Femoral: 
Estudo de Segurança e Eficácia
Introdução: Avaliamos a segurança e eficácia do uso depro-
tamina, guiada pelo tempo de coagulação ativado, para a 
remoção imediata do introdutor arterial femoral em pacientes 
submetidos à intervenção coronária percutânea com heparina 
não fracionada, com o objetivo de propor um algoritmo para 
a prática clínica. Métodos: Estudo prospectivo, com pacientes 
consecutivos, com angina estável ou com síndrome coronariana 
aguda de baixo ou moderado risco. Comparamos os pacientes 
com a retirada precoce do introdutor arterial àqueles nos quais 
o introdutor foi retirado de acordo como protocolo conven-
cional. A decisão pela remoção precoce ou convencional do 
introdutor foi deixada a critério do operador. Resultados: O 
grupo de remoção precoce (n = 149) apresentou menor tempo 
de manuseio do sítio de punção que o grupo de remoção 
convencional (58,3 ± 21,4 minutos vs. 355 ± 62,9 minutos; 
p  <  0,01), principalmente devido à redução do tempo até a 
retirada do introdutor (42,3 ± 21,1 minutos vs. 338,6 ± 61,5 
minutos; p < 0,01), sem impacto sobre a duração da compressão 
femoral (16,0 ± 3,6 minutos vs. 16,4 ± 5,1 minutos; p = 0,49). 
Não houve trombose hospitalar de stent e nem diferença signifi-
cativa na incidênciade eventos vasculares ou hemorrágicos. A 
incidência de outras hemorragias, que levaram à hospitalização 
prolongada, foi menor no grupo de remoção precoce (1,3% vs. 
5,1%; p = 0,05). Conclusões: O uso seletivo de uma abordagem 
para a remoção imediata do introdutor femoral guiada pelo 
tempo de coagulação ativado e a administração de protamina 
são seguros e eficazes em pacientes submetidos à intervenção 
coronária percutânea pela via femoral.
DESCRITORES: Protaminas. Heparina. Intervenção coronária 
percutânea. Artéria femoral. Anticoagulantes.
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T he radial approach for percutaneous coronary intervention (PCI) has gained much attention in recent years, due to its potential to reduce the 
bleeding rates related to the procedure,1 especially 
in patients with acute coronary syndrome. However, 
the need for a femoral approach, after the failure of 
the radial approach, can reach up to 17% in certain 
subgroups of patients.2 In practice, contraindications or 
impossibility of the radial access, along with the prefer-
ence of the doctor and patient, still place the femoral 
approach as an obligatory technique in the portfolio 
of any interventional cardiology laboratory, particularly 
for patients with stable coronary artery disease and low 
risk of bleeding complications.
Despite the fact that anticoagulation with bivali-
rudin during PCI has been proven to be beneficial, 
especially in patients with acute coronary syndrome, 
unfractionated heparin (UFH) still remains as the main 
anticoagulant agent among many, if not the major-
ity, of the procedures around the world.3 Previous 
studies have evaluated the use of protamine after 
PCI to reverse anticoagulation as a strategy to allow 
for an early removal of the sheath and potentially to 
reduce bleeding complications.4,5 In a meta-analysis 
with 6,762 patients, protamine significantly reduced 
bleeding without increasing thrombotic adverse events.4 
Conversely, another study comparing bivalirudin with 
UFH in association with protamine showed better 
results with the first anticoagulation protocol.5
The present study was conducted with the aim of 
evaluating the efficacy and safety of a new algorithm 
for early femoral arterial sheath removal after PCI, com-
pared to the conventional protocol, in patients treated 
in the daily practice of a laboratory of interventional 
cardiology with a large volume of procedures.
METHODS
Study design and population
Between August 2012 and March 2013, 228 con-
secutive patients with stable angina or moderate- or 
low-risk acute coronary syndrome undergoing PCI were 
prospectively included in this study. The decision in 
favor of early or conventional removal of the sheath 
was left to the discretion of the surgeon. Patients with 
early removal of the arterial sheath (Early Removal 
Group) were compared versus those in which the sheath 
was removed according to the conventional protocol 
(Conventional Group) followed by the institution. 
The exclusion criteria were: (1) PCI performed by 
radial approach; (2) use of subcutaneous enoxaparin 
in the last 12 hours; (3) use of oral anticoagulation; (4) 
high-risk coronary syndrome (Thrombolysis in Myocardial 
Infarction [TIMI]  >  4);6 (5) presence of an intracoronary 
thrombus; (6) hemodynamic instability. Bivalirudin was 
not available in Brazil at the time of inclusion of patients; 
thus, all procedures were performed with the use of UFH. 
At the time of the procedure, all patients were being 
treated with dual antiplatelet therapy with acetylsalicylic 
acid (100-300 mg daily) and clopidogrel (loading dose 
300 to 600 mg, at least 6 hours before the procedure, 
followed by 75 mg daily). During the procedure, UFH 
was administered at a dose 70-100 IU/kg. 
Baseline data, on the procedure and the in-hospital 
lenght of stay were prospectively collected as part of a 
dynamic registration approved by the ethics committee 
of our institution.
Protocol of early removal of the sheath 
The early removal of the arterial sheath was based 
on an activated clotting time (ACT)-guided algorithm, 
which included the use of intravenous protamine to 
neutralize the effect of UFH, when necessary (Figure). 
Immediately after the procedure, the ACT was measured. 
The femoral sheath was removed if ACT < 180 seconds. 
If the ACT was between 180 and 250 seconds, or if 
> 250 seconds, 25 mg or 50 mg of protamine (diluted 
in 100  mL of 0.9% saline) was administered intrave-
nously during ten minutes, respectively. Five minutes 
after administration of protamine, a new ACT-guided 
cycle was repeated, as described above. An extra dose 
of protamine was administered, up to a maximum dose 
of 1  mg/100 IU of UFH used in the procedure.
Patients included in the Conventional Group had 
the sheath removed after 4 to 6 hours of the last dose 
of UFH, without measurement of ACT. 
In both groups, the femoral hemostasis was obtained 
by manual compression during at least 15 minutes. 
After removal of the sheath, patients remained on bed 
rest for 6 more hours.
Definitions
The treated lesions were classified according to 
the American College of Cardiology/American Heart 
Association (ACC/AHA). Success of the angiographic 
procedure was defined as the presence of a residual 
stenos is < 30%, absence of dissection, and final TIMI 
flow 3. 
The primary efficacy endpoint was the total time 
of handling of the access site, defined as the sum of 
the time spent for removal of the sheath and the total 
time of compression. The time spent for removal of the 
sheath was computed from the end of the procedure 
until the time at which the sheath was removed. 
The primary safety endpoint was composed by car-
diovascular and cerebrovascular adverse events (death, 
myocardial infarction, stroke, and unplanned myocardial 
revascularization), and by major bleeding and vascular 
complications, combined during hospitalization. All 
causes of death were considered in the analysis. After 
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the procedure, the level of CK-MB mass was systemati-
cally measured in all patients, and myocardial infarction 
was classified as: (1) spontaneous; (2) secondary to an 
imbalance between supply and demand; (3) leading to 
death, with no available biomarkers; (4) post-PCI; (5) 
post-coronary artery bypass graft surgery [CABG]; or 
(6) related to stent thrombosis, according to previously 
established criteria.7 All unplanned reoperations were 
considered in the analysis. Stent thrombosis was classi-
fied as definite, probable, or possible.8 Major vascular 
events and bleeding were defined as (1) associated 
with hemodynamic instability or leading to death; (2) 
requiring invasive therapeutic intervention and/or blood 
cell transfusions; (3) leading to prolonged hospitaliza-
tion; (4) associated with a drop in hemoglobin level of 
≥  3  g/dL; or (5) intracranial hemorrhage. 
Adverse reactions to protamine were classified as 
occurrence of hypotension, low back pain, broncho-
spasm, or skin rash,9 during the procedure or within 
the first 12 hours after its completion.
Statistical Analysis
Categorical variables and adverse events were 
presented as absolute numbers and percentages, and 
compared using the Fisher’s exact test or the chi-squared 
test. Continuous variables were presented as means 
and standard deviations and compared using Student’s 
t-test. All p-values were two-tailed and considered 
significant if <  0.05.
RESULTS
A total of 228 consecutive patients were included 
in the evaluation during the study period. Two-thirds 
of patients (n = 149) underwent early removal of the 
sheath (Early Removal Group) and the others (n = 79) 
followed the institutional protocol (Conventional Group). 
The clinical and angiographic characteristics were simi-
lar between the two groups, except for a higher dose 
of heparin and a tendency towards younger patients 
in the Early Removal Group (Table 1). Approximately 
one-third of patients were diabetic and most showed 
stable coronary disease. Only 6 or 7F sheaths were used, 
and most of the procedures were performed with 6F 
sheaths. Complex lesions were treated in approximately 
70% of patients (types B2 or C). 
In the Early Removal Group, immediately after 
the procedure ACT was < 180 seconds in five patients 
(3.3%), who had the femoral sheath removed without 
the need of protamine administration. For the others, an 
initial dose of 25 or 50  mg of protamine was infused 
in 64 and 80 patients (43.0% and 53.7%, respectively), 
according to the ACT value. A second dose of pro-
tamine was required in 37 patients (24.8%), and only 
one patient (0.7%) required a third dose. In total, the 
Figure – Algorithm for early removal of the femoral arterial sheath after percutaneous coronary intervention via femoral artery. ACT: activated clotting time.
End of
hemostasis 
Assess ACT shortly after the end of the intervention
ACT Result
< 180 seconds ≥ 180 seconds and < 250 seconds ≥ 250 seconds
Remove the sheath and
compress for 15 minutes
Protamine 25 mg Protamine 50 mg
Repeat ACT
Has the bleeding stopped?
No Yes
Compress for 15
minutes more
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mean required dose of protamine was 45.8 ± 18.8 mg.
Patients in the Early Removal Group had a time 
of access manipulation significantly lower than in the 
Conventional Group (58.3 ± 21.4 minutes vs. 355.0 ± 
62.9 minutes, respectively; p  <  0.01), mainly due to 
the reduction in the time until removal of the sheath 
(42.3 ± 21.1 vs. 338.6 ± 61.5 minutes, respectively; 
p <  0.01), with no impact on the duration of femoral 
compression (16.0 ± 3.6 vs. 16.4 ± 5.1 minutes, re-
spectively; p =  0.49) (Table 2). 
There were no adverse cardiac or cerebrovascular 
events during hospitalization, except for a minority of 
patients who had periprocedural myocardial infarction 
(3.4% vs. 2.5%; p > 0.99). The incidence of major vas-
cular events and of bleeding was not different between 
the two groups (3.3% vs. 6.4% respectively; p = 0.32), 
as well as the incidence of a combined safety endpoint, 
which was also similar among groups (6.7% vs. 7.6% 
respectively; p = 0.79). The incidence of other bleeding 
that led to a prolonged hospitalization was lower in 
the Early Removal Group (1.3% vs. 5.1%; p =  0.05). 
Only one patient presented an adverse effect related 
to the administration of protamine, which consisted of 
low back pain, quickly resolved with hydration and 
analgesia.
DISCUSSION
The main result of the present study was that the 
selective use of a stepwise approach for the immedi-
ate removal of the femoral arterial sheath, based on 
an ACT value and followed by the use of protamine 
to antagonize heparin, is safe and effective in reducing 
the manipulation time of the access route in patients 
undergoing PCI. 
Previous studies have examined the use of protamine 
after PCI through femoral route.4,5 In these studies, 
however, protamine was only indistinctly prescribed 
after the procedure, without individualization of its 
use, as proposed in this study. Indeed, the present 
study centered the strategy for early removal of the 
sheath upon the reversal of anticoagulation, rather than 
only a simplistic strategy of a separate administration 
TABLE 1 
Clinical, angiographic, and procedural characteristics
Early removal 
(n = 149)
Conventional 
(n = 79) p-value
Age, years 60.6 ± 17.9 64.8 ± 11.2 0.06
Male, n (%) 101 (67.8) 46 (58.2) 0.19
Weight, kg 75.9 ± 14.3 73.7 ± 15.5 0.28
Height, m 1.66 ± 0.09 1.64 ± 0.09 0.11
Hypertension, n (%) 129 (86.6) 69 (87.3) > 0.99
Previous or current smoking, n (%) 60 (40.3) 32 (40.5) > 0.99
Diabetes mellitus, n (%) 50 (33.6) 28 (35.4) 0.77
Previous acute myocardial infarct, n (%) 46 (30.9) 21 (26.6) 0.54
Previous coronary artery bypass graft surgery, n (%) 24 (16.2) 12 (15.2) > 0.99
Previous percutaneous coronary intervention, n (%) 37 (25.0) 22 (27.8) 0.64
Platelets, 103× cells/mL 244.0 ± 75.5 236.0 ± 61.9 0.42
Acute coronary syndrome at presentation, n (%) 25 (16.8) 9 (11.4) 0.33
Classification of lesions, n (%) 0.77
Type A 9 (6.0) 7 (8.9)
Type B1 29 (19.5) 17 (21.5)
Type B2 51 (34.2) 23 (29.1)
Type C 60 (40.3) 32 (40.5)
Number of stents 1.4 ± 0.7 1.6 ± 1.0 0.08
Mean stent nominal diameter, mm 3.1 ± 0.7 3.0 ± 0.6 0.10
Total length of stents, mm 28.3 ± 16.7 32.5 ± 24.0 0.12
Heparin dose, IU 9.205 ± 1.389 8.741 ± 1.391 0.02
Sheath diameter, n (%) 0.88
6F 108 (72.5) 56 (70.9)
7F 41 (27.5) 23 (29.1)
Ipsilateral puncture ≤ 7 days, n (%) 13 (8.8) 5 (6.3) 0.61
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of protamine. As seen in these patients, when sheath 
removal was guided by an ACT value, there were pa-
tients who did not require the use of protamine; others 
require halfdose, full dose, or even repeating the dose 
of protamine to obtain an early, safe, and effective 
removal of the sheath after PCI via the femoral artery.
Intuitively, the immediate reversal of heparin effect 
after implantation of a coronary stent may increase the 
chances of a hyperacute stent thrombosis. In the present 
series, there were no cases of thrombotic complication 
after protamine administration. It is important to em-
phasize that, in this study, only patients who already 
were treated with dual antiplatelet therapy, who had 
a stable pre- and post-procedure clinical condition, 
and whose result of the intervention was considered 
satisfactory were included. Thus, these findings cannot 
be extrapolated to other clinical settings. 
A relatively large list of potent antithrombotic agents 
is currently available for use in patients treated with 
PCI. However, an aggressive antithrombotic therapy 
proves more beneficial in patients with acute coronary 
syndrome, with less evidence supporting its routine use 
in stable patients.3,10 Similarly, PCI by radial approach 
has been shown to reduce adverse events in acute pa-
tients,11 with few studies showing benefit in those with 
stable coronary disease. Thus, PCI through femoral access 
with the use of UFH for the treatment of patients with 
stable coronary artery disease still remains the primary 
strategy in a large number of countries and institutions. 
In this context, the present study prospectively evaluated 
the use of protamine to obtain an early removal of the 
femoral sheath in a population of patients with stable 
coronary disease, or with acute coronary syndrome of 
low or moderate risk.
The present study had intrinsic limitations, due to 
the fact that it was not randomized, and also due to its 
sample size. Although the incidence of adverse events 
was similar between both groups, the possibility that 
significant differences in complications of low incidence 
could arise, if the sample size was increased, cannot be 
ruled out. However, due to the minimal absolute and 
relative differences in the observed outcomes between 
both groups, it is unlikely that these results would be 
substantially changed, if the sample was increased. 
The patients included in this study were not randomly 
assigned. Thus, the influence of a selection bias in the 
results cannot be completely ruled out. However, this 
study was intended primarily to evaluate the clinical 
performance of the proposed algorithm in a daily clinical 
practice, according to which the strategy of an early 
removal can be used selectively, by analyzing each 
case. Finally, the administration of protamine may be 
associated with side effects. The approach described 
in our study tends to minimize the unwanted effects 
of protamine, reducing the final dose to the minimum 
TABLE 2 
Access site and in-hospital clinical outcomes 
Early removal 
(n = 149)
Conventional 
(n = 79) p-value
Time to remove the sheath, minutes 42.3 ± 21.1 338.6 ± 61.5 < 0.01
Compression time, minutes 16.0 ± 3.6 16.4 ± 5.1 0.49
Total handling time of site access,* minutes 58.3 ± 21.4 355.0 ± 62.9 < 0.01
In-hospital length of stay, days 1.5 ± 3.0 1.5 ± 1.1 > 0.99
Death, n (%) 0 0 NA
Stroke, n (%) 0 0 NA
Myocardial infarction, n (%) 5 (3.4) 2 (2.5) > 0.99
Unplanned revascularization, n (%) 0 0 NA
Stent thrombosis, n (%) 0 0 NA
Pseudoaneurysm, n (%) 1 (0.7) 1 (1.3) > 0.99
Arteriovenous fistula, n (%) 2 (1.3) 0 0.54
Lower limb ischemia, n (%) 0 0 NA
Retroperitoneal bleeding, n (%) 0 0 NA
Transfusion, n (%) 0 0 NA
Other bleeding that led to a prolonged in-hospital 
length of stay,** n (%) 
1 (1.3) 4 (5.1) 0.05
Combined safety endpoint,** n (%) 10 (6.7) 6 (7.6) 0.79
* Primary efficacy endpoint
** Mainly femoral hematoma > 5 cm in diameter.
NA: not applicable.
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needed to neutralize the effect of UFH. In fact, the 
protamine dose used in this study was less than half 
the theoretically recommended dose to neutralize the 
total dose of UFH administered during the procedure.
CONCLUSIONS
The selective use of an approach for immediate 
removal of the femoral arterial sheath, guided by the 
value of activated coagulation time and followed by the 
administration of protamine, is a safe and effective option 
in patients with stable coronary artery disease undergoing 
percutaneous coronary intervention by femoral access.
ACKNOWLEDGMENTS
The authors thank Mrs. Patricia Pereira, Paula Fields, 
and Irineia Aleixo, for their invaluable support.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING SOURCE
None.
REFERENCES
1. Bertrand OF, Belisle P, Joyal D, Costerousse O, Rao SV, Joseph 
L, et al. Comparison of transradial and femoral approaches 
for percutaneous coronary interventions: a systematic re-
view and hierarchical Bayesian meta-analysis. Am Heart J. 
2012;163(4):632-48.
2. Michael TT, Alomar M, Papayannis A, Mogabgab O, Patel VG, 
Brilakis ES, et al. A randomized comparison of the transra-
dial and transfemoral approaches for coronary artery bypass 
graft angiography and intervention: The RADIAL-CABG Trial 
(RADIAL Versus Femoral Access for Coronary Artery Bypass 
Graft Angiography and intervention). JACC Cardiovasc Interv. 
2013;6(11):1138-44.
3. De Servi S, Mariani G, Mariani M, D’Urbano M. The bi-
valirudin paradox: high evidence, low use. J Cardiovasc 
Med.2013;14(5):334-41.
4. De Luca G, Parodi G, Antoniucci D. Safety and benefits of 
protamine administration to revert anticoagulation soon after 
coronary angioplasty: a meta-analysis. J Thromb Thromboly-
sis.2010;30(4):452-8.
5. Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, 
Moschi G, et al. Comparison of bivalirudin and unfraction-
ated heparin plus protamine in patients with coronary heart 
disease undergoing percutaneous coronary intervention (from 
the Antithrombotic Regimens and Outcome [ARNO] trial). Am 
J Cardiol. 2010;105(8):1053-9.
6. Sabatine MS, Antman EM. The thrombolysis in myocardial 
infarction risk score in unstable angina/non-ST-segment el-
evation myocardial infarction. J Am Coll Cardiol. 2003;41(4 
Suppl S):89S-95S
7. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, 
White HD, et al. Third universal definition of myocardial 
infarction. Circulation. 2012;126(16):2020-35.
8. Serruys PW, Daemen J. Are drug-eluting stents associated with 
a higher rate of late thrombosis than bare metal stents? Late 
stent thrombosis: a nuisance in both bare metal and druge-
luting stents. Circulation. 2007;115(11):1433-9.
9. Lindblad B. Protamine sulphate: a review of its effects: hyper-
sensitivity and toxicity. Eur J Vasc Surg. 1989;3(3):195-201.
10. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller 
U, et al. A randomized trial of prasugrel versus clopidogrel in 
patients with high platelet reactivity on clopidogrel after elec-
tive percutaneous coronary intervention with implantation of 
drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet 
Reactivity in Patients Undergoing Elective Stent Placement on 
Clopidogrel to Guide Alternative Therapy with Prasugrel) study. 
J Am Coll Cardiol. 2012;59(24):2159-64.
11. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, et al. 
The transradial versus the transfemoral approach for primary 
percutaneous coronary intervention in patients with acute 
myocardial infarction: A systematic review and meta-analysis. 
Euro Intervention. 2012;8(4):501-10.
